drugset / Trial / NCT01214642
A Dose-Escalation Study for Patients With Advanced Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).
Timeline
- Start
- 2008-05
- Primary completion
- 2011-12
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | litronesib | Small molecule | 2 mg/m2 | Intravenous |
| Subject | litronesib | Small molecule | 8 mg/m2 | Intravenous |
| Subject | litronesib | Small molecule | 12 mg/m2 | Intravenous |
| Background | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |
Indications
No indication recorded.